Moxidectin
Moxidectin is a small molecule pharmaceutical. Moxidectin was first approved as Moxidectin on 2018-06-13. It is used to treat ocular onchocerciasis in the USA.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Moxidectin
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
MOXIDECTIN | Medicines Development for Global Health | N-210867 RX | 2018-06-13 | 1 products, RLD, RS |
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
ocular onchocerciasis | EFO_0007398 | D015827 | B73 |
Agency Specific
FDA
EMA
Expiration | Code | ||
---|---|---|---|
MOXIDECTIN, MOXIDECTIN, MDGH | |||
2025-06-13 | ODE-193 | ||
2023-06-13 | NCE |
Patent Expiration
No data
HCPCS
No data
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | MOXIDECTIN |
INN | moxidectin |
Description | Moxidectin is a milbemycin. |
Classification | Small molecule |
Drug class | antiparasitics (ivermectin type) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CO/N=C1\C[C@]2(C[C@@H]3C[C@@H](C/C=C(\C)C[C@@H](C)/C=C/C=C4\CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)O[C@H](/C(C)=C/C(C)C)[C@H]1C |
Identifiers
PDB | — |
CAS-ID | 113507-06-5 |
RxCUI | — |
ChEMBL ID | CHEMBL2104415 |
ChEBI ID | — |
PubChem CID | 9832912 |
DrugBank | DB11431 |
UNII ID | NGU5H31YO9 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,744 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more